Previous studies have revealed that SurR9-C84A replaces the depleted endogenous survivin in normal brain cells and helps in their proliferation (Baratchi et al., 2010; Sriramoju et al., 2014), while in the case of cancer cells, SurR9-C84A binds to the highly overexpressed survivin to form a heterodimer and leading to its degradation by ubiquitination and apoptosis (Cheung et al., 2010; Roy et al., 2015a). This evidence concerns the gene BIRC5 and cancer.